Oric Pharmaceuticals (ORIC) executive compensation, 2026 proxy

Jacob M. Chacko, M.D., President and Chief Executive Officer, was paid $5.6M in 2025, up 5% from $5.3M the year before.

Filed
April 28, 2026
Annual meeting
June 18, 2026
Pay year
2025
Named executives
3
CEO total pay
$5.6M+5% vs prior year
CEO pay in equity
80%$4.5M in awards
CEO 2025 Base Salary
$657,500As reported in Summary Compensation Table
CEO Target Bonus
55%Expressed as percentage of base salary
Bonus Plan Funding
120%Based on achievement of company objectives

How M.D. was paid

$5.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary12%Stock awards15%Option awards65%Non-equity incentive8%All other compensation0%

Named executive officers

ExecutiveTotal
Jacob M. Chacko, M.D.President and Chief Executive Officer$5,567,164
Dominic PiscitelliChief Financial Officer$2,237,425
Pratik Multani, M.D.Chief Medical Officer$2,282,441

What changed and why

  • $5.6MJacob M. Chacko total compensation increased to $5,567,164 in 2025 from $5,282,815 in 2024.
  • 5%Base salary for the CEO increased approximately 5% to $660,000 for 2025.
  • 120%The 2025 bonus plan was funded at 120% of target based on performance objectives.
  • 55%CEO target bonus opportunity was set at 55% of base salary for 2025.
  • Stock options and restricted stock units were granted to named executive officers on January 2, 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.